Please login to the form below

Not currently logged in
Email:
Password:

Ferring agrees Chinese reproductive medicine research deal

Work with the Chinese Academy of Sciences on the long-term project

Ferring

Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) are set to collaborate on a long-term project to advance basic and translational research in reproductive medicine.

The project will see the duo develop novel product candidates and therapeutic strategies in a jointly funded laboratory based in the CAS research facility in Beijing, China.

Known as the ‘Ferring Institute of Reproductive Medicine’, the facility will bring together researchers from both Ferring and CAS to find solutions that will address global challenges in fertility and high rates of obstetric complications.

Per Falk, executive vice president and chief scientific officer of Ferring Pharmaceuticals, said: “Across the world too many couples still face considerable challenges when trying to become families.

“This collaboration forms the next phase in our ongoing effects to advance knowledge and care in reproductive medicine and women’s health.”

The pharmaceutical group has said that they hope to gain a deeper understanding of fertility and implantation, with the aim of discovering new solutions.

Professor Hongemi Wang, director of the state key laboratory, CAS, said: “Our collaboration with Ferring will expand our research base into the translational space and together we will rapidly expand our tool set to look at truly transformational ideas in reproductive medicines.”

CAS has an additional interest in the collaboration, as it will provide expertise and funding to support their stem cell research and regenerative medicine, a core element of their Innovation 2030: Building Tomorrow initiative, which aims to improve reproductive health both in China and worldwide.

Article by
Gemma Jones

12th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics